Fulgent Genetics Q1 2026 Earnings Call Insights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy FLGT?
Source: seekingalpha
- Financial Overview: Fulgent Genetics reported Q1 2026 revenue of $71.1 million, slightly above analysts' expectations of $68.1 million, despite facing a decline in sales from its largest customer, indicating stability amidst challenges.
- Acquisition Impact: The successful acquisition of Bako Diagnostics and StrataDx contributed $2.6 million in revenue and more than doubled the size of the pathology sales team, which is expected to enhance market competitiveness and drive future growth through integration.
- Profitability Outlook: The company anticipates a non-GAAP gross margin of 39% for 2026, with expectations to improve to 42% by year-end, despite current pressures from decreased sales volume and claims processing backlog, reflecting management's confidence in restoring profitability.
- Future Guidance: Fulgent reiterated its total revenue guidance of $350 million for 2026, projecting an 8.5% year-over-year growth, while updating EPS expectations to reflect the impact of stock repurchases, indicating a cautiously optimistic outlook on future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FLGT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FLGT
Wall Street analysts forecast FLGT stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 14.130
Low
30.00
Averages
32.50
High
35.00
Current: 14.130
Low
30.00
Averages
32.50
High
35.00
About FLGT
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Fulgent Genetics Q1 2026 Earnings Call Insights
- Financial Overview: Fulgent Genetics reported Q1 2026 revenue of $71.1 million, slightly above analysts' expectations of $68.1 million, despite facing a decline in sales from its largest customer, indicating stability amidst challenges.
- Acquisition Impact: The successful acquisition of Bako Diagnostics and StrataDx contributed $2.6 million in revenue and more than doubled the size of the pathology sales team, which is expected to enhance market competitiveness and drive future growth through integration.
- Profitability Outlook: The company anticipates a non-GAAP gross margin of 39% for 2026, with expectations to improve to 42% by year-end, despite current pressures from decreased sales volume and claims processing backlog, reflecting management's confidence in restoring profitability.
- Future Guidance: Fulgent reiterated its total revenue guidance of $350 million for 2026, projecting an 8.5% year-over-year growth, while updating EPS expectations to reflect the impact of stock repurchases, indicating a cautiously optimistic outlook on future performance.
See More
Fulgent Genetics Reports Q1 Earnings Miss with Revenue Beat
- Earnings Performance: Fulgent Genetics reported a Q1 non-GAAP EPS of -$0.36, missing expectations by $0.01, indicating ongoing challenges in profitability.
- Revenue Insights: The company generated $71.1M in revenue, a 3.3% year-over-year decline, yet surpassed market expectations by $3.01M, suggesting a resilient market demand despite challenges.
- Gross Profit Analysis: GAAP gross profit stood at $21.5M with a gross margin of 30.2%, while non-GAAP gross profit was $23.0M with a gross margin of 32.3%, reflecting efforts in cost management.
- Future Outlook: Fulgent Genetics forecasts $350M in revenue for 2026, aiming for a 53% annual growth rate driven by acquisitions of Bako and StrataDx to reshape its customer mix.
See More
Fulgent Genetics Q1 Earnings Announcement Scheduled
- Earnings Announcement: Fulgent Genetics is set to announce its Q1 earnings on May 1 before market open, with consensus EPS estimate at -$0.35 and revenue estimate at $68.09 million, reflecting a 7.4% year-over-year decline.
- Historical Performance: Over the past two years, Fulgent has beaten EPS estimates 100% of the time and revenue estimates 63% of the time, indicating a strong track record of financial performance.
- Estimate Revision Trends: In the last three months, there have been no upward revisions to EPS estimates, with one downward revision, while revenue estimates also saw no upward revisions and two downward revisions, suggesting market caution regarding future performance.
- Future Projections: Fulgent forecasts $350 million in revenue for 2026 with a projected 53% annual growth rate, indicating a strategic shift in customer mix driven by acquisitions of Bako and StrataDx to enhance future growth prospects.
See More
Fulgent Genetics Under Investigation for Securities Law Violations
- Financial Performance Miss: Fulgent Genetics reported approximately $322.7 million in revenue for the full year 2025 on February 27, 2026, which slightly missed the previously updated guidance, indicating pressure in market competition.
- Quarterly Revenue Decline: The company experienced a sequential decline in fourth-quarter revenue, suggesting ongoing operational challenges that could impact investor confidence and lead to stock price volatility.
- Legal Investigation Initiated: Lowey Dannenberg P.C. is investigating potential violations of federal securities laws by Fulgent, and if confirmed, this could expose the company to legal liabilities and compensation risks.
- Investor Loss Focus: The investigation has drawn attention from investors who suffered losses in Fulgent securities, potentially prompting more investors to seek legal remedies to recover losses, further affecting the company's reputation.
See More
Fulgent Genetics Under Investigation for Securities Violations
- Financial Performance Decline: Fulgent Genetics reported approximately $322.7 million in revenue for the full year 2025, slightly missing the updated guidance, indicating pressure in market competition that could undermine investor confidence.
- Quarterly Revenue Drop: The company's fourth-quarter revenue declined sequentially, reflecting weak business growth that may raise investor concerns about future performance, potentially impacting stock price.
- Legal Investigation Initiated: Lowey Dannenberg P.C. is investigating whether Fulgent violated federal securities laws, and if confirmed, this could lead to legal liabilities and financial losses for the company, further eroding shareholder confidence.
- Investor Loss Risk: Investors who suffered losses in the company's securities may participate in litigation, increasing the legal risks faced by the company and affecting its market reputation and future financing capabilities.
See More
Fulgent Genetics to Release Q1 2026 Financial Results
- Earnings Release Schedule: Fulgent Genetics will announce its Q1 2026 financial results before the market opens on May 1, 2026, reflecting the company's ongoing development in technology-based and laboratory services.
- Investor Conference Call: Management will host a conference call at 8:30 AM ET on the same day to discuss the financial results and answer investor questions, enhancing transparency and investor confidence.
- Business Transformation Strategy: Fulgent is transitioning from a traditional diagnostic business to a fully integrated precision medicine company, focusing on developing drug candidates for various cancers using a novel nanoencapsulation and targeted therapy platform to improve drug efficacy.
- Laboratory Services Overview: The company's laboratory services include technical laboratory and testing services, along with professional interpretation of results by licensed physicians, showcasing its expertise and competitiveness in the healthcare service sector.
See More
Fulgent Genetics Q1 2026 Earnings Call Insights
- Financial Overview: Fulgent Genetics reported Q1 2026 revenue of $71.1 million, slightly above analysts' expectations of $68.1 million, despite facing a decline in sales from its largest customer, indicating stability amidst challenges.
- Acquisition Impact: The successful acquisition of Bako Diagnostics and StrataDx contributed $2.6 million in revenue and more than doubled the size of the pathology sales team, which is expected to enhance market competitiveness and drive future growth through integration.
- Profitability Outlook: The company anticipates a non-GAAP gross margin of 39% for 2026, with expectations to improve to 42% by year-end, despite current pressures from decreased sales volume and claims processing backlog, reflecting management's confidence in restoring profitability.
- Future Guidance: Fulgent reiterated its total revenue guidance of $350 million for 2026, projecting an 8.5% year-over-year growth, while updating EPS expectations to reflect the impact of stock repurchases, indicating a cautiously optimistic outlook on future performance.
See More
Fulgent Genetics Reports Q1 Earnings Miss with Revenue Beat
- Earnings Performance: Fulgent Genetics reported a Q1 non-GAAP EPS of -$0.36, missing expectations by $0.01, indicating ongoing challenges in profitability.
- Revenue Insights: The company generated $71.1M in revenue, a 3.3% year-over-year decline, yet surpassed market expectations by $3.01M, suggesting a resilient market demand despite challenges.
- Gross Profit Analysis: GAAP gross profit stood at $21.5M with a gross margin of 30.2%, while non-GAAP gross profit was $23.0M with a gross margin of 32.3%, reflecting efforts in cost management.
- Future Outlook: Fulgent Genetics forecasts $350M in revenue for 2026, aiming for a 53% annual growth rate driven by acquisitions of Bako and StrataDx to reshape its customer mix.
See More
Fulgent Genetics Q1 Earnings Announcement Scheduled
- Earnings Announcement: Fulgent Genetics is set to announce its Q1 earnings on May 1 before market open, with consensus EPS estimate at -$0.35 and revenue estimate at $68.09 million, reflecting a 7.4% year-over-year decline.
- Historical Performance: Over the past two years, Fulgent has beaten EPS estimates 100% of the time and revenue estimates 63% of the time, indicating a strong track record of financial performance.
- Estimate Revision Trends: In the last three months, there have been no upward revisions to EPS estimates, with one downward revision, while revenue estimates also saw no upward revisions and two downward revisions, suggesting market caution regarding future performance.
- Future Projections: Fulgent forecasts $350 million in revenue for 2026 with a projected 53% annual growth rate, indicating a strategic shift in customer mix driven by acquisitions of Bako and StrataDx to enhance future growth prospects.
See More
Fulgent Genetics Under Investigation for Securities Law Violations
- Financial Performance Miss: Fulgent Genetics reported approximately $322.7 million in revenue for the full year 2025 on February 27, 2026, which slightly missed the previously updated guidance, indicating pressure in market competition.
- Quarterly Revenue Decline: The company experienced a sequential decline in fourth-quarter revenue, suggesting ongoing operational challenges that could impact investor confidence and lead to stock price volatility.
- Legal Investigation Initiated: Lowey Dannenberg P.C. is investigating potential violations of federal securities laws by Fulgent, and if confirmed, this could expose the company to legal liabilities and compensation risks.
- Investor Loss Focus: The investigation has drawn attention from investors who suffered losses in Fulgent securities, potentially prompting more investors to seek legal remedies to recover losses, further affecting the company's reputation.
See More
Fulgent Genetics Under Investigation for Securities Violations
- Financial Performance Decline: Fulgent Genetics reported approximately $322.7 million in revenue for the full year 2025, slightly missing the updated guidance, indicating pressure in market competition that could undermine investor confidence.
- Quarterly Revenue Drop: The company's fourth-quarter revenue declined sequentially, reflecting weak business growth that may raise investor concerns about future performance, potentially impacting stock price.
- Legal Investigation Initiated: Lowey Dannenberg P.C. is investigating whether Fulgent violated federal securities laws, and if confirmed, this could lead to legal liabilities and financial losses for the company, further eroding shareholder confidence.
- Investor Loss Risk: Investors who suffered losses in the company's securities may participate in litigation, increasing the legal risks faced by the company and affecting its market reputation and future financing capabilities.
See More
Fulgent Genetics to Release Q1 2026 Financial Results
- Earnings Release Schedule: Fulgent Genetics will announce its Q1 2026 financial results before the market opens on May 1, 2026, reflecting the company's ongoing development in technology-based and laboratory services.
- Investor Conference Call: Management will host a conference call at 8:30 AM ET on the same day to discuss the financial results and answer investor questions, enhancing transparency and investor confidence.
- Business Transformation Strategy: Fulgent is transitioning from a traditional diagnostic business to a fully integrated precision medicine company, focusing on developing drug candidates for various cancers using a novel nanoencapsulation and targeted therapy platform to improve drug efficacy.
- Laboratory Services Overview: The company's laboratory services include technical laboratory and testing services, along with professional interpretation of results by licensed physicians, showcasing its expertise and competitiveness in the healthcare service sector.
See More
